ResearcherShenyang Pharmaceutical UniversityActive in the last 2 years

Xue Bing Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-9687-8806; OpenAlex author ID A5100422571. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

MGST1 facilitates novel KRAS G12D inhibitor resistance in KRAS G12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis. Co-author DOI 10.1186/s10020-024-00972-y ↗
Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer. Co-author DOI 10.1007/s13346-020-00884-4 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chungui Xu · 1 shared paper, 2024 · strength 0.20
- Paper MGST1 facilitates novel KRAS G12D inhibitor resistance in KRAS G12D-mutated pancreatic ductal adenocarcinoma by inhibit… DOI 10.1186/s10020-024-00972-y ↗
Chunxia Du · 1 shared paper, 2024 · strength 0.20
- Paper MGST1 facilitates novel KRAS G12D inhibitor resistance in KRAS G12D-mutated pancreatic ductal adenocarcinoma by inhibit… DOI 10.1186/s10020-024-00972-y ↗
X S Wang · 1 shared paper, 2024 · strength 0.20
- Paper MGST1 facilitates novel KRAS G12D inhibitor resistance in KRAS G12D-mutated pancreatic ductal adenocarcinoma by inhibit… DOI 10.1186/s10020-024-00972-y ↗
Yongjun Wang · 1 shared paper, 2021 · strength 0.13
- Paper Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with O… DOI 10.1007/s13346-020-00884-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.